Biofortuna launches its new approach to custom IVD manufacture and development services

Diagnostics company Biofortuna will mark the 2015 AACC Annual Meeting and Clinical Lab Expo in Atlanta, USA, with the launch of a broader portfolio of custom manufacturing and development services for the IVD market.

World-renowned for its lyophilisation services and molecular diagnostic products, Biofortuna has developed a new internal infrastructure, creating distinct products and services divisions and giving the company a strong focus for growth and efficiency. The breadth of the company’s portfolio of IVD manufacturing and development services has expanded to include manufacturing, dispensing, kitting, labelling, capping, as well as design and development of molecular diagnostic kits.

Tuesday, July 28, 2015

Biofortuna Ltd appoints new Chairman to lead next phase of growth

UK based molecular diagnostics company Biofortuna has appointed a new Chairman to lead the next phase of growth.

Life sciences expert Ian Johnson will take on the role at Biofortuna with previous Chairman Mark Hurley remaining on the board as a Non-executive Director.

Biofortuna, based in the Wirral, specialises in proprietary freeze-dried diagnostics and

Tuesday, February 24, 2015

Biofortuna Ltd closes a £1.5m funding round

Biofortuna Ltd, the UK based molecular diagnostics company specialising in its proprietary freeze-dried diagnostics and contract services, announces raising £1.5m in its latest funding round.

The £1.5m funding was supported by all the company’s current investors; Foresight VCTs, Catapult Ventures, Enterprise Ventures, MSIF, private investors and management.

The new funding is for Biofortuna to develop a portfolio of new molecular diagnostic

Thursday, January 29, 2015

Biofortuna expands its infrastructure and production capacity

Biofortuna Ltd, a molecular diagnostics company based in Wirral UK, announces significant expansion of its freeze dried (lyophilization) production service. Due to an increased demand of companies outsourcing their freeze-dried production of diagnostic kits, Biofortuna has invested in a new state of the art freeze-dryer together with additional climate control units.

The additional freeze drier and infrastructure almost doubles production capacity allowing Biofortuna to accommodate the ever increasing demand of its freeze dried contract service.

Friday, August 8, 2014

Biofortuna receives FDA clearance of its SSPGo™ line of HLA molecular diagnostic freeze-dried kits

For immediate release: Biofortuna, a UK based molecular diagnostics company with proprietary freeze drying (lyophilizing) technology, has received FDA 510K clearance for its line of SSPGo™ HLA PCR kits. The SSPGo HLA Typing Kits are qualitative DNA-based kits for determining HLA alleles in low to intermediate resolution. The kits are designed for transplantation genotyping and identification of genes which may be associated with various genetic conditions.

Tuesday, February 25, 2014

Previous Page | Next Page